ReviewHormones (Athens, Greece)2026
Genetic risk factors for diabetic retinopathy in the Greek population: a review of key gene polymorphisms.
Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes mellitus and a leading cause of visual impairment among adults worldwide. While hyperglycemia and metabolic dysregulation are recognized contributors to DR pathogenesis, increasing attention has been directed toward the role of genetic factors. This review evaluates the association between specific single nucleotide polymorphisms (SNPs) and DR susceptibility within the Greek population, an underrepresented group in global genomic studies. The review synthesizes findings from population-specific research focused on eight genes, namely, ADIPOQ, AGER, ALDH2, UCHL3, HNMT, PAI-1 (SERPINE1), SLC2A1, and NOS3. Variants in these genes have been implicated in key pathways related to inflammation, oxidative stress, endothelial dysfunction, and glucose metabolism. Several polymorphisms, including ADIPOQ rs1501299, AGER rs1051993, ALDH2 rs671, and NOS3 rs1799983, were associated with increased DR risk, while others showed associations with disease progression or early onset. Importantly, some polymorphisms revealed ethnic-specific effects not observed in other populations, highlighting the importance of localized genetic studies. These findings are hypothesis-generating and further research is required to replicate these associations, clarify underlying mechanisms, and assess gene-environment interactions before considering any potential clinical translation.
Indexed as
Identifiers
42484804What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.